GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 51 [WO2022175752]
Compound class:
Synthetic organic
Comment: Voderdeucitinib is the INN for a (deuterated) Janus kinase inhibitor with anti-inflammatory potential (included in WHO INN proposed list 133, 10th July 2025). The chemical structure is claimed in patent WO2022175752 as a TYK2 inhibitor (TYK2 is a member of the Janus kinases family) [1]. The compound targets the TYK2 pseudokinase (JH2) domain, so is an allosteric inhibitor. The developer is SUDO biosciences who specialise in TYK2 inhibitor development, with 4 declared programmes in their pipeline, including two named inhibitors SUDO-550 (brain-penetrant, for neuroinflammatory diseases; phase 1) and SUDO-286 (topical, for immune-mediated dermatologic diseases; phase 1).
|
|
Bioactivity Comments |
Inhibits IL-23 and IFNα production by specialised HEK293 cell lines, with IC50 values <30 nM and 30-300nM respectively [1]. Does not inhibit kinase activity of JAKl, JAK2, JAK3 and TYK2 kinase domain (JH1) constructs in vitro. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|